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ABSTRACT 
Background  
Vagus nerve stimulation (VNS) is an adjunctive palliative neuromodulatory 
treatment for drug resistant epilepsy (DRE) and chronic depression. It has 
also been proposed as a treatment for many other conditions such as chronic 
pain, heart failure, and Alzheimer’s disease. Vagal Blocking Therapy 
(VBLOC) was recently approved for the treatment of obesity. However, the 
mechanisms of action still remains unclear and its long-term safety and 
efficacy in combination with antiepileptic drugs (AEDs) needs to be further 
evaluated. The aim of this thesis was to study the action of VNS on 
hippocampal neurogenesis as a possible mechanism of action on depression, 
to evaluate VBLOC as a new treatment model for obesity, and to study the 
long-term safety and effectiveness of VNS.  
 
Patients and methods 
In Study I rats were implanted with VNS and different stimulation 
parameters were compared to sham, in order to evaluate the effect of VNS on 
hippocampal progenitor proliferation. The number of Bromodeoxiuridine 
(BrdU) positive cells was compared between groups. In Study II rats were 
implanted with VBLOC, and leads were placed around the gastric portion of 
the vagus nerve. Body weight, food intake, hunger/satiety, and metabolic 
parameters were monitored and compared between control and sham-
stimulated animals. In Study III all patients that had been implanted with 
VNS between 1990 and 2014 were analyzed for surgical and hardware 
complications. In Study IV data from 130 consecutive patients implanted 
with VNS between the years 2000 and 2013 was analyzed for seizure 
frequency and AEDs prior to VNS implantation as well as at 1, 2, and 5 years 
postoperatively. Study III and IV were retrospective cohort studies. 
 
Results 
VNS at the output current of 0.75 mA for 48 hours showed a significant 
increase in progenitor cell proliferation. VBLOC reduced food intake and 
body weight, and was associated with increased satiety but not with 
decreased hunger. Complications occurred in 8.6 % of all VNS surgeries in 
patients with DRE. The most common complications, all with an occurrence 
rate of about 2 %, were postoperative hematoma, infection, and vocal cord 
paralysis. Hardware related complications occurred in 3.7 % of all implanted 
VNS systems, and significantly less lead associated complications occurred 
during 2000–2014 compared to 1990–1999. There was a significant seizure 
reduction overall (all p<0.001) regardless of AED regimen, and VNS efficacy 
increased with time from 22.1 % at 1 year to 43.8 % at 5 years.  
  
Conclusions  
VNS induces stem cell proliferation in the rat hippocampus, which supports 
the notion that hippocampal plasticity is involved in the antidepressant effect 
of VNS. The mechanism of action of VBLOC as a treatment for obesity could 
be regulated by inducing satiety through vagal signaling, leading to reduced 
food intake and loss of body weight. The treatment was well tolerated in rats. 
VNS is a safe palliative neuromodulatory treatment for DRE, and the 25 years 
of follow-up to study safety is of great strength considering that VNS can be a 
life-long treatment with repeated surgeries. VNS efficacy increased with 
time, with improvements seen up to 5 years, and did not differ between 
patients that had altered or remained on the same AEDs throughout the 
study period. 
 
Keywords  
Vagus nerve stimulation, VNS, Neuromodulation, Neurogenesis, VBLOC, 
Epilepsy, Depression, Safety, Efficacy, Effectiveness 
 SAMMANFATTNING PÅ SVENSKA 
Vagusnervstimulering (VNS) är framför allt en tilläggsbehandling vid svårbehandlad 
epilepsi där mediciner inte har tillräcklig effekt mot upprepade krampanfall. 
Behandlingen är också godkänd mot kronisk och recidiverande depression. VNS innebär 
att man med hjälp av en inopererad elektrod på halsen stimulerar den vänstra 
vagusnerven (även kallad den 10:e kranialnerven, n. X). Elektroden kopplas till en 
stimulator som placeras under huden nedanför vänster nyckelben. Elektriska impulser 
skickas via vagusnerven till hjärnan och det hela kan liknas vid en slags pacemaker. På så 
sätt försöker man minska antalet epileptiska anfall eller behandla svår depression. VNS 
har också testats som behandling mot exempelvis hjärtsvikt, kroniska smärttillstånd och 
Alzheimers sjukdom. Nyligen godkändes en ny typ av VNS mot övervikt, så kallad VBLOC. 
Trots omfattande forskning och trots att VNS använts kliniskt sedan början av 1990-talet 
känner man fortfarande inte till de exakta verkningsmekanismerna. När det gäller 
operationsrelaterade komplikationer och behandlingseffekt i kombination med 
antiepileptiska mediciner över lång tid finns det begränsade data.  
Målet med denna avhandling var att studera en möjlig verkningsmekanism för 
VNS på stamceller i råttans hippocampus, vilket skulle kunna utgöra en del i den 
antidepressiva effekten. Det var även att utvärdera en ny möjlig behandlingsmetod mot 
övervikt samt att studera risken för komplikationer i samband med VNS-inläggning och 
effektiviteten av VNS över en längre tidsperiod.  
VNS effekt på cellnybildning i hippcampus och dess möjlighet att minska 
födointag undersöktes i två separata studier på råtta. Samtliga råttor fick VNS inopererade 
och därefter jämfördes stimulerade och icke-stimulerade råttor. I två andra studier 
insamlades data för samtliga patienter som opererats med VNS vid neurokirurgiska 
kliniken på Sahlgrenska Universitetssjukhuset mellan åren 1990 och 2014. 
Komplikationspanorama, komplikationsfrekvens samt effekten av VNS, och då även i 
förhållande till förändringar i antiepileptisk läkemedelsbehandling, utvärderades.  
VNS-stimulerade råttor hade ett signifikant större antal nybildade celler i 
hippocampus jämfört med icke-stimulerade råttor men effekten var dosberoende. 
VBLOC-stimulerade råttor hade mindre födointag och minskade i vikt jämfört med 
kontrollgruppen. Komplikationer till VNS-inläggningar och batteribyten inträffade i 8,6 % 
av samtliga fall. Blödning, infektion och stämbandspares var de vanligast förekommande 
komplikationerna. I 3,7 % av fallen uppkom tekniska fel i den inopererade utrustningen. 
Oavsett antiepileptisk medicinering så minskade antalet epileptiska anfall signifikant med 
VNS. VNS-effekten ökade över tid från 22,1 % till 43,8 % över 5 år. Dock minskade inte 
läkemedelsanvändningen hos mer än ett fåtal patienter, och överlag ökade den signifikant. 
 Studierna i avhandlingen visar att ökningen av antalet celler i hippocampus kan 
vara en effekt av VNS, vilket är en möjlig antidepressiv verkningsmekanism. VBLOC 
tolererades väl av försöksdjuren och tycktes påverka mättnad, vilket resulterade i 
viktminskning. Försöken talar för att VBLOC är en metod som kan användas som 
behandling mot övervikt. Kliniskt tillämpad VNS är en säker behandlingsmetod med 
förhållandevis låga risker även ur ett långtidsperspektiv. Dessutom ses en ökad 
behandlingseffekt över tid. 
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INTRODUCTION 
Definition and brief history 
Therapeutic neuromodulation is defined by the International 
Neuromodulation Society as “the alteration of nerve activity through 
targeted delivery of a stimulus, such as electrical stimulation or chemical 
agents, to specific neurological sites in the body”1. By stimulating the nervous 
system with non-invasive or minimally invasive neuromodulating devices, 
modulation in neural signaling and function can be achieved, possibly 
resulting in molecular, physiological, and behavioral alterations. 
Neuromodulatory treatments for disorders such as epilepsy, depression, 
chronic pain, Parkinson’s disease, tremor, as well as restoration of bowel and 
bladder control have been developed in the last decades. The first described 
use of neuromodulation occurred in about 15 A.D. when a man suffering from 
gout accidentally stepped on an electric fish, and after the shock noticed 
much less pain2. Several pioneering discoveries in the fields of electricity and 
neurophysiology by Galvani, Fritsch and Hitzig, and Bartholow amongst 
many others in the early 18th and 19th century, laid the groundwork for the 
understanding and further development of modern neurostimulators, such as 
vagus nerve stimulation (VNS), deep brain stimulation (DBS), and spinal 
cord stimulation (SCS)3. Today neuromodulation is a rapidly developing field 
with new and more targeted treatments and therapies for many different 
conditions. 
The vagus nerve – anatomy and function 
The vagus nerve (the tenth cranial nerve, n. X) is the longest of the cranial 
nerves. As a consequence of its long and complex course from the brain stem 
to the abdomen, its name is derived from the Latin word for wanderer4. It is a 
mixed nerve containing both efferent and afferent fibers that are attached to 
multiple rootlets in the medulla. Approximately 20 % of the vagus nerve 
fibers are efferent and originate from the dorsal motor nucleus and the 
nucleus ambiguus in the medulla oblongata. These fibers provide 
parasympathetic innervation to essentially all the thoracic and abdominal 
organs as well as project motor neurons to striated muscles of the pharynx 
and larynx5. As for all parasympathetic nerves, the fibers do not innervate 
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peripheral organs directly but via parasympathetic ganglia close to or in the 
walls of the organs. The postgangliotic neurons are then connected to the 
cardiovascular, respiratory, and gastrointestinal organs.6 The remaining 80 % 
of the vagus nerve fibers are afferent. Most of the neurons contributing 
afferent input to the cervical vagus nerve, found in the carotid sheath, have 
cell bodies located in the jugular and the nodose ganglion, which are situated 
at and immediately below the jugular foramen. Nerve fibers from these 
ganglia transmit visceral, somatosensory, and taste sensations to the brain via 
medullary nuclei. The nerve consists of myelinated A-, B-, and unmyelinated 
C-fibers, and conduction velocities are proportional to their sizes. Large 
myelinated A-fibers carry mostly somatic afferent and efferent information, 
and small myelinated A-fibers primarily transmit visceral afferent 
information, B-fibers provide efferent and parasympathetic preganglionic 
innervation, and small unmyelinated C-fibers primarily carry afferent 
visceral information4,6. At the cervical level most vagus nerve fibers (60-80 
%) are afferent C-fibers7. The vast afferent direct and indirect projections 
from the vagus nerve to multiple higher deep, subcortical, and cortical brain 
centers, mainly via the nucleus tractus solitarius (NTS), are considered to 
play an important role in the mechanism of action of VNS in treating 
epilepsy and mood disorders6. Other vagal sensory afferent projections from 
the external auditory meatus, the posterior fossa meninges, the larynx, and 
the upper esophagus are 
received in the spinal nucleus 
of the trigeminal nerve and 
relayed to the sensory cortex 
via the thalamus8. The vagus 
nerve is also known to play an 
important role in mediating 
vital digestive reflexes and 
influence digestive behavior9. 
Nutritional and metabolically 
relevant information is 
conveyed to the brain by gut-
produced hormones and the 
vagus nerve10. To sum up, the 
extensive spread of afferent 
projections from the vagus 
nerve has raised the question if 
VNS can be developed into a 
successful treatment in other 
areas such as heart failure, 
Alzheimer’s disease, obesity, 
and pain.  
 
Figure 1. Illustration of the vagus nerve 
anatomy and its connection to visceral 
organs (retrieved from http://medical- 
dictionary.thefreedictionary.com). 
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Vagus nerve stimulation (VNS) 
VNS is a neuromodulatory treatment for drug resistant epilepsy (DRE) and 
chronic or refractory depression. A bipolar electrode is placed around the left 
cervical vagus nerve, and direct electrical modulatory access to subcortical 
brain areas are generated by a pulse generator placed in the chest wall. 
Because of the nerve’s location it provides a unique entrance to the brain11. 
In the early 1990’s the Neurological and Neurosurgical Department at 
Sahlgrenska University Hospital was one of the first centers involved in 
implanting VNS when clinical trials were initiated12,13. VNS has since then 
been approved for the treatment of refractory epilepsy since 1994 in Europe 
and 1997 in the USA. It was also approved for treating chronic and recurrent 
depression in 2001 in Europe and 2005 in the USA. Even though more than 
100.000 devices have been implanted in around 80.000 patients worldwide, 
its mechanism of action still remains unclear, and its clinical safety and 
efficacy is frequently debated. As VNS can be a life-long treatment, it is of 
great importance to have long-term follow-up data regarding efficacy and 
tolerability.  
Historically in the late 19th century, the American neurologist Corning 
suggested that stimulating the vagus nerve, by compressing the carotid 
arteries and at the same time stimulating the vagus nerve electrically, could 
interrupt epileptic seizures by reducing cerebral blood flow. Corning, 
amongst other scientists, believed that seizures were associated with 
alterations of cerebral blood flow, and by creating a crude and external VNS 
in the 1880s, he lowered the number of seizures in patients treated with 
cardioinhibitory vagus stimulation14. However, it was not until 1952 that 
Zanchetti et al showed that vagal afferent stimulation directly affected 
cortical activity.  Epileptic activity in their animal model could be suppressed 
depending on stimulation frequency15. In the 1980s, Zabara began to analyze 
the effect of VNS on chemically induced seizures in dogs, and the results 
were remarkably positive16. Since that time VNS has become a globally 
accepted form of treatment for epilepsy.  
VNS implantation 
VNS implantation is considered to be a minimally invasive surgical 
procedure. Nevertheless, the implantation should be performed by a surgeon 
with detailed familiarity with the procedure. Surgery is performed under 
general anesthesia and prophylactic antibiotics are administered to minimize 
the risk of infection. Via a transverse incision lateral to the thyroid cartilage 
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on the neck, the left vagus nerve is carefully dissected in its carotid sheath 
between the carotid artery medially and the internal jugular vein laterally. At 
least 3 cm of the nerve has to be exposed in order for the wrapping of the 
bipolar electrodes. A silicone lead consisting of a helical anchor, anode, and 
cathode is wrapped around the nerve. The negative electrode (cathode) is 
placed cranially, and the positive electrode (anode) caudally. The lead is then 
tunneled subcutaneously to an incision below the left collarbone, where a 
subcutaneous pocket is made. To avoid tension on the lead, it is looped in a 
gentle curve and sutured to soft tissue adjacent to the nerve. The lead is then 
connected to a pulse generator and placed in the subcutaneous pocket over 
the left major pectoral muscle17,18. The stimulator can also be placed in a 
submuscular (subpectoral) pocket19. If no adverse event occurs, the patients 
are usually discharged from the hospital the day after surgery. 
 
 
Figure 2A. Showing a schematic drawing of the skin incision on the left    
side of the neck and the cervical anatomy. 2B. Illustrating the wrapping 
technique of the lead electrodes around the vagus nerve. (Courtesy of 
Journal of neurosurgery Pediatrics and the artist Andrew Rekito) 
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When the pulse generator is about to be depleted a battery replacement is 
made, usually under local anesthetics with prophylactic antibiotics 
administered. If no adverse event occurs, the patients are discharged from 
the hospital the same day.  
 
Figure 3. Showing the VNS lead in place with the negative electrode cranially 
and the anchor tether caudally and a schematic picture of the lead and 
stimulator in place. (Courtesy of Daniel Nilsson and Lancet neurology) 
 
 
In Studies I and II, rat VNS implantation was made in a similar fashion. 
Because the vagus nerve of the rat is substantially thinner than the human, 
the surgical procedure was always made under microscopical control in order 
to decrease mechanical nerve manipulation. The VNS electrode was also 
modified to better fit the smaller and more delicate nerve in the rat. For 
details see the materials and methods section. 
Stimulation parameters 
VNS can be administered with a range of at least five different use 
parameters (intensity, frequency, pulse width, on-time, and off-time). The 
pulse generator is initiated 2 weeks after implantation. The rationale for the 
time delay is the concept of nerve swelling following surgery20. The device is 
started at 0.25 mA, 30 Hz, and 500 μsec pulse width for 30 seconds on and 5 
minutes off. If patients complain of vocal side effects, the frequency is 
reduced to 20 Hz and pulse width to 250 μsec. To improve efficacy, the 
settings are adjusted in some patients to 30 seconds on and 1.8 or 3 minutes 
off. Rapid cycling has been tried in some patients (7 seconds on and 21 
seconds off), but because of shortened battery life and lack of improved 
efficacy21, all patients were reverted back to 30 seconds on and 1.8–5 minutes 
Anchor  
Tether 
Positive  
Electrode 
Negative  
Electrode 
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off. There is also a possibility to initiate extra stimulation using a magnet that 
comes with the VNS system. The most common use of the magnet is when a 
seizure is anticipated or in progress, and the idea is to try to abort a seizure at 
the initial phase22. Invariably, the magnet settings are one notch higher than 
the regular stimulation. The stimulation parameters are increased gradually 
with 0.25 mA to the highest tolerable setting. Maximum output current is 3.5 
mA, and frequencies of 50 Hz, since higher current and frequencies may 
cause major irreversible damage to the vagus nerve23. VNS parameters can 
easily be adjusted by the treating physician or nurse with a programming 
wand placed over the pulse generator. 
For stimulation parameters and programming in the rat, see the materials 
and methods section. 
Surgical complications 
Surgical complications can be divided into complications as a result of the 
actual invasive procedure e.g. vocal cord paralysis and postoperative 
hematoma, and into hardware complications such as lead break/fractures or 
lead malfunction. The most common complication to VNS implantation is 
postoperative infection followed by postoperative hematoma and vocal cord 
paralysis, but other more uncommon complications such as jugular vein 
puncture and pneumothorax have also been reported18,24,25. Arrhythmia, 
including asystole and bradycardia, is an important but rare complication 
that has been reported in the literature26-30. Because of anatomical 
differences between the left and right vagus nerve, where the right vagus 
nerve carries most of the parasympathetic fibers that more densely innervate 
the sinoatrial node, stimulation of the left vagus nerve, innervating the 
atrioventricular node, is favored to avoid affection of the cardiac rhythm31. 
Most long-term safety data ranges from 1 to 5 years and are summarized in 
Table 1. VNS implantation in children has been carried out since 1994. The 
complication panorama is of the same kind as for adults except for a higher 
infection rate in the pediatric population32,33. Generally, if a postoperative 
wound infection occurs, it is most often initially treated with oral, and in 
some cases intravenous antibiotics. If the infection persists, which is usually 
the case with deep wound and pocket infections, the stimulator needs to be 
removed in order to treat the infection32,34.  
 
 
For surgical complications in the rat, see the materials and methods section. 
 
 
    Introduction 21 
Table 1. Occurrence of complications to VNS related surgeries in the literature 
 Adults Children 
Surgical complications   
Hematoma 0.2 – 1.9 %18,24,25  
Infections 2.0 – 7.0 %18,24,25,32,35-40 2.9 – 12.5 %34,41-43 
Vocal cord paralysis 1.0 – 5.6 %18,24,25,35,38,39 
 
1.4 %34 
Facial palsy 0.2 %18  
Pain and sensory related  1.1 – 2.0 %18,36,38,40 2.4 %34 
Bradycardia 0.7 – 9.95 %24,39   
Puncture of jugular vein 2.1 %24  
Large cutaneous nerve cut off 0.7 %24  
Aseptic reaction 0.2 – 2.9 %18,36  
Cable discomfort 0.2 %18  
Surgical cable break 0.2 %18  
Oversized stimulator pocket 0.2 %18  
Battery displacement 0.2 %18  
Technical complications   
Lead fracture/lead malfunction 2.9 – 11.9 
%18,24,25,36,38,39,44 
0.0 – 20.8 %34,41-43 
Spontaneous VNS turn on  0.2 – 1.4 %18,24  
Lead disconnection 0.5 – 2.8 %18,24,39  
 
Stimulation tolerability 
The most common stimulation related side effects are voice alterations, 
hoarseness, cough, dyspnea, paresthesia or tingling sensation, headache, and 
pain45. Usually they are mild to moderate and most often improve with 
time46. Stimulation related side effects can also be reduced or avoided by 
altering stimulation parameters, usually by reducing the output current, but 
also by lowering stimulation frequency and decreasing pulse width47.   
Hoarseness and voice alterations are the results of efferent stimulation of the 
recurrent laryngeal nerve with its innervation of the striated muscles of the 
larynx which branches off distally to the implanted electrodes48,49. 
Paresthesia or tingling sensation is believed to be a result of secondary 
stimulation of the superior laryngeal nerve, which supports the laryngeal 
mucosa with sensory nerve fibers and branches off from the vagus nerve 
proximally to the implanted electrodes50. The possible cardiac side effects of 
VNS, such as bradycardia, ventricular asystole, and complete heart block, are 
constantly under discussion from a safety perspective. They mainly occur in 
the operating room during initial device testing, and rarely emerge years 
after VNS implantation27-30. Possible reasons for this phenomenon could be 
polarity reversal of the leads during implantation casing efferent instead of 
afferent stimulation51, indirect stimulation of the cervical cardiac nerves, 
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technical malfunction of the implanted device, differences in anatomical 
innervation, or accidental over-manipulation of the nerve when placing the 
leads around it. Implantation of the electrodes can be more or less 
challenging and time consuming due to anatomical variations in the 
implantation area. Only sporadic cases of late VNS related cardiac side 
effects have been reported in the literature52-54. Another possible effect of 
stimulating efferent fibers of the vagus nerve is hypersecretion of gastric acid 
due to its efferent innervation of the visceral mucosa. However, no 
significant side effects on gastrointestinal vagus nerve function, such as 
gastric ulcers, have been reported in both short- and long-term studies13,55. 
Unique side effects such as drooling and increased hyperactivity have been 
reported in children56.  
Epilepsy 
Epilepsy is the second most common neurological illness after 
cerebrovascular disease, with a prevalence of approximately 0.5–1.0 %. An 
estimated 50 million people suffer from epilepsy worldwide.57-59 In Sweden 
there are about 60.000 people suffering from epilepsy60. The causes of 
epilepsy are heterogeneous, ranging from genetic defects, structural 
abnormalities, metabolic diseases, infections of the central nervous system 
(CNS), neurodegenerative disorders, brain injury, stroke, to brain tumors61. 
Classification of epileptic seizures are divided into focal onset seizures that 
are conceptualized as originating at some point within networks limited to 
one hemisphere, and generalized seizures that are conceptualized as 
originating at some point within one hemisphere and rapidly engaging 
bilaterally distributed networks. Focal seizures can manifest themselves 
differently and vary in severity depending on the area of onset. They may 
occur with or without affecting the patient’s consciousness or awareness, and 
can also spread to become a bilateral seizure. Genetic generalized seizures 
are subdivided into tonic-clonic, absence, myoclonic, clonic, tonic, and atonic 
seizures. These are further subdivided according to the clinical and 
electroencephalographic (EEG) features62. Patients are evaluated with 
respect to medical history, semiology, imaging (magnetic resonance 
tomography, MRI), and EEG. 
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Epilepsy is a disease of the brain defined by any of the following conditions:59 
1.  At least two unprovoked (or reflex) seizures occurring > 24 h apart 
 
2. One unprovoked (or reflex) seizure and a probability of further 
seizures similar to the general recurrence risk (at least 60%) after 
two unprovoked seizures, occurring over the next 10 years 
 
3. Diagnosis of an epilepsy syndrome  
 
Antiepileptic drugs (AEDs) are by far the most common and usually the first-
line treatment for epilepsy. The mechanisms of action of AEDs at a 
molecular level are not yet fully understood, and in some cases seem to have 
multiple molecular targets63. The main mechanisms, however, are involved 
in restoring the cellular firing equilibrium within the brain through blockage 
of voltage-gated ion channels. Thus, potentiating inhibitory 
neurotransmitters and modulating excitatory transmission64. Most patients 
can successfully be treated with one or multiple AEDs, but despite the 
continuing development of new AEDs, and the rapid progress of diagnostic 
techniques, 20–30 % of patients with epilepsy do not respond to treatment 
sufficiently65,66. This may have a devastating effect on both patients and their 
families, as DRE can cause major individual suffering and poor quality of life. 
DRE can be defined as a seizure frequency exceeding one per month and 
failure of more than two AEDs67,68. If complete seizure control is not 
achieved with trials of two appropriate AEDs, the likelihood of success with 
subsequent regimens is much reduced and drops to about 5 %69,70. Adverse 
effects from AEDs such as somnolence, dizziness, and cognitive impairment 
are common and can become intolerable even if the drug itself is effective in 
treating the epilepsy. It may necessitate either discontinuation or dose 
reduction if symptoms are felt to be unbearable71. Other treatment options 
available are participating in clinical trials of newly developed AEDs, 
epilepsy surgery, dietary treatments, immunological treatments, and 
neuromodulation72.    
VNS is usually used as a palliative antiepileptic treatment for patients that 
have been evaluated with respect to possible epilepsy surgery, or have been 
subjected to failed epilepsy surgery. In Sweden it is the consensus that 
patients with DRE must first be evaluated for the possibility of resective 
epilepsy surgery before being offered VNS. 
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VNS mechanism of action in epilepsy 
Today the most common and widely used neuromodulatory treatment for 
DRE is VNS73. Since its introduction as a non-pharmacological treatment for 
epilepsy, numerous studies have been conducted to explain and understand 
its mechanisms of action. Despite extensive research no single mechanism of 
action has been shown to mediate the antiepileptic effect of VNS, hence the 
mechanism is believed to be complex and multifactorial. It is feasible that the 
VNS effect in humans is primarily mediated by afferent A- and B-fibers74,75. 
Selective destruction of C-fibers with capsaicin does not affect VNS-induced 
seizure suppression in rats76. Moreover, therapeutic VNS appears to be sub-
threshold for C-fibers48.  
 
Functional imaging studies have shown that unilateral VNS affects both 
cerebral hemispheres via projections from the NTS to higher cerebral 
nuclei77,78. Widespread VNS-induced metabolic changes occurred in brain 
regions involved in seizure generation including the thalamus, cerebellum, 
orbitofrontal cortex, limbic system, hypothalamus, and medulla79. Initially it 
was hypothesized that the main mechanism of action of VNS consisted of 
desynchronization of neuronal activity, since epilepsy is considered to be a 
disease of cortical origin as well as the fact that epileptic seizures are 
characterized by highly synchronized EEG activity. VNS has also been shown 
to alter EEG activity in animal studies80-84. Furthermore, experimental 
animal studies have demonstrated that VNS reduces cortical excitability and 
decreases interictal epileptiform EEG discharges15,85-88. Brain structures that 
have been shown to play a role in regulation or generation of seizures, such 
as the amygdala, the hippocampus, and parts of the thalamus, are directly 
and indirectly connected to the vagus nerve via the NTS in the brain stem 
and could cause desynchronization as a result of VNS89-91. There is increasing 
evidence that these afferent polysynaptic pathways from the NTS to cortical 
regions mediate its antiepileptic action through an increased synaptic 
activity in the thalamus and thalamo-cortical projection pathways, and 
through a decreased synaptic activity in the limbic system11.   
A modulated release of several neurotransmitters have also been linked to 
the antiepileptic effect of VNS. VNS have been shown to decrease the levels 
of excitatory neurotransmitters in cerebrospinal fluid92-94. VNS also induces 
increased levels of the inhibitory neurotransmitter GABA92. It has been 
hypothesized that VNS is effective because it affects the ratio between the 
excitatory neurotransmitter glutamate, which is extensively released during 
seizures, and GABA95. Moreover, locus coerulius (LC), the most important 
source of noradrenaline (NA) in the brain, seems to be crucial for the 
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antiepileptic effects of VNS since the seizure-suppressive effects of VNS 
were averted by lesioning the LC96. The vagus nerve both directly and 
indirectly projects to the LC and raphe nuclei4,5,97,98, and basal firing rate of 
serotoninergic neurons in the dorsal raphe nucleus of the rat have also been 
shown to increase after chronic VNS99-101. Furthermore, there is growing 
evidence suggesting that nitric oxide and acetylcholine release can be 
mediated by VNS102,103. Hippocampal plasticity may also play a role in the 
antiepileptic action of VNS, possibly mediated via an increased NA 
concentration104,105. Moreover, VNS has been shown to induce an increase in 
the extracellular hippocampal concentrations of NA, and at the same time 
decrease seizures in an animal model106. Interestingly, in this study there was 
also a “responder-rate” similar to observations in clinical trials. Growing 
evidence suggests that VNS has a neuroimmunomodulatory effect, which is 
believed to be another antiepileptic mechanism of VNS107-110.  
Depression 
Major depressive disorder (MDD) is a life-threatening disease with increased 
risk of mortality and severe human suffering for the affected individuals. The 
lifetime prevalence is reported to be as high as 16–17 %111,112. Depression is a 
global illness found in all races, cultures, and socioeconomic groups. The 
World Health Organization estimates that MDD will be the second largest 
cause of global disease in the world by 2020 after ischemic heart disease113. 
The prevalence of the depressive disease has been continually increasing in 
recent years with an alarming trend of increasingly younger people being 
afflicted. The one-year prevalence in Sweden is estimated to be 5–8 %114 
costing society approximately 35 billion Swedish kronor per year115. The 
cause of depression is multifactorial, but there are two main hypotheses for 
the development of depression in humans, the monoamine and the neural 
plasticity hypotheses. The monoamine hypothesis proposes that depression 
is caused by a deficiency in monoaminergic levels and transmission, mainly 
serotonin (5-HT) and NA116-118, and current pharmacological treatments are 
mainly focused on restoring this chemical imbalance in different ways by 
increasing the levels of monoamines in the CNS119. Although antidepressants 
produce a rapid increase in extracellular levels of NA and 5-HT, the onset of 
an appreciable clinical effect usually takes at least 3 to 4 weeks, and this delay 
suggests that slow neurochemical and structural changes take place within 
the limbic target areas of monoaminergic projections120. More recently a new 
hypothesis for the development of depression in humans has been formed 
which includes neurogenesis as a factor of importance in the depressive 
disease. The hypothesis states that reduction of neurogenesis in the 
hippocampus is a causality factor in the generation of depression, and that 
 The neuromodulatory effect, safety and effectiveness of Vagus Nerve Stimulation 26 
stimulated neurogenesis is part of the recovery process from the depressive 
state121,122. This theory was proposed when the birth of new neurons from 
neuronal stem cells, the process called neurogenesis, was discovered and 
observed in the adult brains of both rodents and humans123,124. This process 
of neurogenesis is especially prominent in the hippocampus, a brain area and 
part of the limbic system known to be involved in mood and memory 
functions125. 
 
Over the last three decades antidepressant pharmacological treatment have 
been successfully developed, and new medications are continuing to emerge 
on the market. Despite this, up to 20 % fail to respond appropriately to 
antidepressant treatment126 and, furthermore, the risk of recurrence and 
chronic depression increases with failure to reach full clinical remission127. 
Some of the chronic and recurrent cases can be successfully treated with 
electroconvulsive therapy, although usually temporarily. Thus, it is 
important to find new non-pharmacological well-tolerated treatments with 
mild to moderate side effects. VNS treatment can be an adjunctive long-term 
treatment for depression, and it can be offered to patients with chronic or 
recurrent depression who are experiencing a major depressive episode and 
have not had an adequate response to four or more antidepressant 
treatments128. Although approved in the USA as well as in Europe, the 
Swedish National Board of Health does not recommend the use of VNS as an 
adjunctive antidepressant treatment, as they still consider the evidence for 
clinical efficacy to be limited129. 
VNS mechanism of action in depression 
Early on, positive effects on mood were reported in patients treated with 
VNS for epilepsy130, even regardless of the effects on seizure frequency131,132. 
Several clinical trials have later shown beneficial effects of VNS on 
depression133-135. However, the underlying mechanism of action of VNS on 
depression is still not fully known. As described earlier hippocampal 
plasticity seems to be affected by VNS, and a possible mechanism is 
increased levels of NA and 5-HT in the hippocampus. Earlier studies in rat 
have shown an increased firing rate of neurons in both the LC and the dorsal 
raphe nucleus as a result of VNS99,100,105. This could increase the progenitor 
cell proliferation and possibly facilitate adult neurogenesis, the production of 
new and fully functional neurons within the brain of an adult organism. Adult 
neurogenesis is primarily restricted to the subventricular zone and the 
subgranular zone of the dentate gyrus (DG) of the hippocampus123. These 
neurons are generated from neural stem and progenitor cells in the 
subgranular zone and migrate into the granular cell layer, where they 
differentiate into neurons136. These cells are then integrated into the 
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hippocampal circuitry137,138. Hippocampal volume-loss in patients with MDD 
has been reported in several studies. A large amount of data suggests that 
increased levels of cortisol results in neuronal death in the hippocampus in 
animal models139,140. Hypercortisolism is known to be an important factor in 
stress-induced depression141, and is a strong inhibitor of neurogenesis142. 
About 40-60 % of medicine-free depressed patients exhibit pathologically 
high levels of cortisol143,144. It has been shown that decreased hippocampal 
volume may be a sensitive marker of underlying brain pathology in    
MDD145-147, and that hippocampal volume may predict clinical outcome in 
major depression148. Several studies have shown that antidepressants induce 
hippocampal volume increase in both animal models and humans with 
depression compared to healthy controls149-151. MRI studies show smaller 
(10–20 % reduction) hippocampal volumes in depressed patients152,153, which 
could indicate a decreased neurogenesis or increased neuronal apoptosis in 
this brain structure. Recent studies have shown that hippocampal volume 
increase after electroconvulsive therapy in patients with depression, 
suggesting a dynamic response to the treatment154,155. In animal studies, 
inhibition of hippocampal neurogenesis by irradiation impairs 
antidepressant efficacy120.  
Short-term VNS in rats showed an increase in progenitor cell proliferation in 
the DG after 48 hours, suggesting a rapid effect of VNS; however, the 
survival of the progenitor cells was not affected by VNS156. Similarly, another 
study in rats, using short-term (3 hours) and long-term (1 month) VNS, found 
increased progenitor cell proliferation only in the short-term experiments157. 
On the other hand, chronic VNS induced a long-lasting increase in the 
expression of brain-derived neurotrophic factor (BDNF) and basic fibroblast 
growth factor (bFGF), important modulators of hippocampal plasticity and 
neurogenesis104,157. Electroshock therapy has also been shown to stimulate 
cell proliferation in the hippocampus more rapidly than antidepressant drugs 
in animal studies158.  
Taken together, there is convincing data supporting VNS effect on 
hippocampal plasticity and depression. However, these studies are mainly 
performed on animals, and there is still need for further clinical trials in 
evaluating the efficacy of the actual treatment. 
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VNS and obesity 
Obesity is an increasingly growing problem in the developed and the 
developing world159. In some countries such as the USA the prevalence is 
reaching epidemic proportions160. A major concern is the increased risk of 
accompanying comorbidities, such as diabetes, cardiovascular disease, and 
cancer161. So far only bariatric surgery (weight loss surgery) has 
demonstrated long-term therapeutic effects, and therefore the use of surgery 
to treat obesity is on the rise162,163. Nevertheless, this elective surgery carries 
risks for considerable morbidity and potential mortality. A large meta-
analysis of >22,000 patients reported the mortality rate for gastric bypass at 
0.5 %164, with different studies publishing a mortality range of 0 % to 1.5 %165-
168. Considering the risk for surgical complications and high surgery-related 
costs, it has been proposed that the development of minimal invasive 
procedures to treat obesity is urgently needed169. The central role of the 
vagus nerve in the regulation of food intake and energy expenditure, the 
vagal afferent activity or the so-called gut-brain axis, is activated by 
mechanoreceptors and chemoreceptors in the gut and converge in the NTS 
of the brainstem. Neuronal projections from the NTS, in turn, carry signals 
to brain areas such as the hippocampus and hypothalamus.10 The 
hypothalamus and the brainstem are the main CNS regions responsible for 
the regulation of energy homeostasis170. The NTS governs the responses of 
the organs responsible for energy and metabolic control through the dorsal 
motor nucleus of the vagus nerve and its efferent fibers. This makes the 
vagus nerve an ideal target for new less or noninvasive procedures to treat 
obesity. VNS has been shown to have a positive effect on weight reduction in 
experimental studies171,172. Conversely, it did not affect body weight in VNS 
treated patients with epilepsy173,174. Recently, the Food and Drug 
Administration (USFDA) has approved vagal blocking therapy (VBLOC), by 
which an intra-abdominal electrical device with leads is placed 
laparoscopically around the vagus nerve, as a new treatment for obesity175,176. 
It is hypothesized that VBLOC activates the vagal signaling to the brainstem 
and hippocampus and blocks the vagal signaling to the gut, leading to 
increased satiety, reduced food intake, and eventually loss of body weight. 
However, the mechanism of action is unclear and remains to be further 
elucidated. 
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Effectiveness of VNS in epilepsy 
In the USA, VNS is currently approved as adjunctive therapy for partial onset 
seizures in patients over 12 years of age, with medically intractable partial 
seizures who are not candidates for potentially curative surgical resections 
such as lesionectomies or mesial temporal lobectomies. In Europe, VNS is 
approved at any age for patients with refractory epilepsy. In the recently 
updated guideline from the American Academy of Neurology (AAN), it is 
stated that: “VNS may be considered for seizures in children, for Lennox-
Gastaut syndrome-associated seizures, and for improving mood in adults 
with epilepsy. VNS may also be considered to have improved efficacy over 
time. Especially children should carefully be monitored for site infection 
after VNS implantation”177. In general, ≥50 % seizure reduction rate is 
considered as an effective VNS treatment. Since its introduction, several 
meta-analyses and reviews regarding treatment efficacy has been presented, 
including a Cochrane review on VNS for partial seizures (updated in 2015)178. 
As is the usual scenario, the randomized-control trials were all short-term 
studies and did not account for long-term follow-up concerning efficacy and 
safety12,131,179,180. Many of the registry and retrospective long-term studies 
investigating the efficacy of VNS show that there is an approximately 50 % 
seizure frequency reduction in about 40–60 % of the implanted 
patients25,41,181. However, when analyzing the majority of these studies, there 
is a widespread variation in follow-up time, number of patients included, and 
duration of study. Data from 48 long-term follow-up studies (mean ≥12 
months) are presented in Table 2. Three of the studies are prospective open 
label studies without randomization. One with exclusively a pediatric 
population, one with no AED changes during its 18 months of follow-up, and 
one that comprises of patients with low IQ. Only one additional study has 
investigated the efficacy of VNS without changing AEDs for 12 months182. 
Approximately half of the studies take into account what kind of AEDs the 
patients are treated with, but only a limited number of the studies describes 
the actual changes in AEDs and the effect on seizure frequency46. So far, 
there have been no studies attempting to match the number of AEDs with 
the individual seizure frequency reduction. Usually the variation in the 
number of AEDs is presented for the cohort as a whole.   
Different evaluation scales have been used to determine the efficacy of VNS. 
Thus, comparing results can be challenging since different studies use 
different protocols and evaluation methods. The Engel classification was 
originally suggested as a standard outcome scale after resective epilepsy 
surgery183, but has been modified and used in VNS studies. The McHugh 
classification was, however, proposed as an evaluation scale for patients 
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treated specifically with VNS184. The McHugh classification has “magnet use 
only” as a single parameter, but only a small number of studies account for 
the magnet use.  
Considering that a large number of patients treated with VNS have multiple 
medications both prior and after VNS implantation, it is important to analyze 
how these medications might influence both VNS and patient outcomes. 
Since many patients with DRE also suffer from comorbidities, there may be 
other medications and possible interactions to consider as well185. Only a 
small number of studies take into account other measures, such as quality of 
life, improved life situation, activity of daily life, cost-benefit analyses, and 
number of hospital admissions186-188. The ongoing discussion about efficacy 
and safety should in the future include an overall effectiveness evaluation, 
including quality of life and possible AED alterations.  
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Table 2. Long-term VNS studies in the literature 
Study 
No. 
cases 
Seizure 
type 
Notes 
Follow-up 
(months) 
No. of 
centers 
% resp-
onders 
AED 
changes 
reported 
Pakdaman et 
al., 2016189 
44 Mixed 
 
60 Single 11 Yes 
Majoie et al., 
2005190 
19 Mixed 
Children 
Prospective 
24 Single 21 .No 
Lund et al., 
2011191 
48 Mixed 
Learning 
disabilities 
16-143 
mean 55 
Single 25 Yes 
Ardesch et al., 
2007192 
19 Focal 
 
24-72 
mean 48 
Single 25 (6 yrs) Yes 
Huf et al., 
2005193 
40 NR 
Adults, low IQ 
Prospective 
24 Single 28 Yes 
Galbarriatu et 
al., 2015194 
59 Mixed 
 
6-102 
mean 39 
Single 34 No 
Vale et al., 
2011188 
37 Mixed QoL assessm. 
18-120 
mean 60 
Single  35* Yes 
Buoni et al., 
2004195 
13 Mixed 
 
8-36 
mean 22 
Single 38 No 
Spanaki et al., 
2004196 
26 Mixed 
 
60-84 
mean 67 
Single 38 Yes 
Hui et al., 
2004197 
13 Mixed 
 
18-71 
mean 47 
Single 40 No 
Menascu et al., 
2013198 
44 Mixed QoL assesm. 18 Single 43 Yes 
Benifla et al., 
2006199 
41 Mixed Children 
6-72 
mean 31 
Single 43 No 
Orosz et al., 
2014200 
347 Mixed Children 24 Multi 44 Yes 
Morris et al., 
199946 
440 Mixed  36 Multi 44 Yes 
Ben-Menachem 
et al., 1999201 
64 Mixed 
 
3-64 
mean 20 
Single 45 No 
Murphy et al., 
200343 
96 Mixed 
 
12-108 
mean 32 
Single 45 Yes 
Arhan et al., 
2010202 
24 Mixed Children 
6-100 
mean 41 
Single 45 No 
Scherrmann et 
al., 200121 
95 Mixed 
 
6-36 
mean 16 
Single 45 No 
Tanganelli et 
al., 200240 
47 Mixed 
 
6-50 
mean 26 
Single 47 No 
Majkowska-
Zwolinska et al., 
2012203 
56 Mixed Children 
12-48 
mean 35 
Single 50 Yes 
Saneto et al., 
2006204 
43 Mixed Children 
7-40 
mean 18 
Single 51 No 
Coykendall et 
al., 201042 
28 Mixed Children 
3-96 
mean 41 
Single 52 (1yr) No 
Vonck et al., 
2008 
27 NR  
19-71, 
mean 42 
Single 52 Yes 
You et al., 
2007205 
28 Mixed Children 
12-79 
mean 31 
Single 54 No 
Vonck et al., 
2004206 
118 Mixed Prospective 
6-94 
mean 33  
Multi 55 Yes 
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Study 
No. 
cases 
Seizure 
type 
Notes 
Follow-up 
(months) 
No. of 
centers 
% resp-
onders 
AED 
changes 
reported 
Kabir et al., 
200936 
69 Mixed Children 
6-120 
mean 46 
Single 
56 (Engel 
class I-III) 
No 
Alexopoulos et 
al., 200641 
46 Mixed Children 
12-48 
med. 24 
Single 59 Yes 
Aburahma et 
al., 2015207 
28 Mixed Children 
36-78 
mean 62 
Multi 59 No 
De Herdt et al., 
2007181 
138 Mixed 
 
12-120 
mean 44 
Multi 59 Yes 
Uthman et al., 
2004208 
48 Focal 
 
4-144 
mean 38 
Single 60 Yes 
Qiabi et al., 
2011209 
34 Mixed 
 
24-46 
mean 30 
Single 60 (3 yrs) Yes 
Choi et al., 
2013210 
20 Mixed 
 
48 Single 60 (4 yrs) Yes 
Ryzi et al., 
2013211 
15 Focal Children 24 and 60 Single 
60 (2 yrs) 
60 (5 yrs) 
Yes 
Chavel et al., 
2003212 
29 Focal 
 
mean 20 Single 61 No 
Arcos et al., 
2014213 
37 Mixed  mean 39 Single 62 No 
Garcia-
Navarrete et al., 
2013214 
43 Mixed Prospective 18 Single 63 Yes 
Nagarajan et 
al., 2002215 
16 Mixed Children 
6-47 
mean 25 
Single 63 Yes 
Serdaroglu et 
al., 2016216 
56 Mixed Children 
60-186 
mean 87 
Single 63 Yes 
Kuba et al., 
200938 
90 Mixed 
 
66-82 
mean 79 
Multi 64 (5 yrs) Yes 
Meng et al., 
2015217 
94 Mixed 
 
6-65 
mean 42 
Multi 64 No 
Elliott et al., 
201125 
400 Mixed 
 
3-132 
mean 59 
Single 64 Yes 
Elliott et al., 
2011218 
141 Mixed Children 
1-137 
mean 62 
Single 65 Yes 
Vonck et al., 
1999219 
15 Mixed 
 
12-48 
mean 29 
Single 67 Yes 
Kawai et al., 
2002220 
13 Focal 
 
48-91 
med. 56 
Single 69 Yes 
Rychlicki et al., 
200644 
34 Mixed Children 
3-36 
mean 31 
Single 71 Yes 
Bodin et al., 
2016221 
29 Mixed Children 24 and 60 Single 75 Yes 
Al Said et al., 
2015222 
26 Mixed 
 
24 Single 78 Yes 
Elliott et al., 
2011223 
65 Mixed 
 
120-139 
mean125 
Single 91 Yes 
AED = antiepileptic drugs, responders = patients with ≥50 % seizure reduction,       
* responders = >30 % seizure reduction 
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VNS and other treatments 
Regarding the widespread afferent and efferent innervation of the vagus 
nerve to multiple inner organs, and its projections to multiple higher 
subcortical and cortical brain centers, VNS has been evaluated in the 
treatment of several other disorders. Most of the theories behind using VNS 
as an alternative treatment for other illnesses have developed after case 
reports from patients receiving VNS for epilepsy, such as the positive mood 
effects noticed early on130. Several studies on the possible neuroprotective 
effects of VNS have been conducted showing a possible effect on 
cognition224,225. These cognitive effects are believed to be mediated via an 
increase of noradrenergic levels in the hippocampus226. A small study on 
Alzheimer’s disease was performed where patients were evaluated with 
neuropsychological tests. The results suggested a positive impact on the 
disease and VNS was well tolerated in this older age group227. However, 
further studies are needed to evaluate the mechanisms and effects of VNS 
treatment on Alzheimer’s disease and cognition.  
There are an increasing number of studies supporting the use of VNS for 
multiple sustained pain conditions such as chronic pelvic pain, fibromyalgia, 
trigeminal allodynia, as well as chronic headaches and migraine. The 
mechanisms of action are still unclear, but there is increasing evidence 
suggesting anti-inflammatory effects working in conjunction with both 
central and peripheral pain pathways228. 
In chronic heart failure, reduced vagus nerve activity is associated with 
increased mortality229 and is characterized by an autonomic imbalance with 
increased sympathetic activity230. VNS has been shown to be beneficial in 
chronic heart failure in both experimental and clinical studies with improved 
left ventricular hemodynamics and decreased mortality230-232. However, in 
the recently published multicenter randomized INOVATE-HF trial, there 
was no reduction in the rate of death or heart failure events in chronic heart 
failure patients233. 
In recent years there has been increasing evidence that VNS is 
neuroimmunomodulatory. This could possibly reduce the inflammatory 
response to brain ischemia and decrease the extent or improve the recovery 
after stroke. Conceivably it could also suppress inflammation in rheumatoid 
arthritis, inflammatory bowel disease, and multiple sclerosis.234-237 
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In summary, with its widespread connections to the CNS, stimulation of the 
vagus nerve can potentially affect the entire human body. It has been 
suggested that an adequate name for the vagus nerve should be “the great 
wandering protector” considering its involvement in autonomic, 
cardiovascular, respiratory, gastrointestinal, immune, and endocrine 
systems4. 
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AIMS 
The overall aim of this thesis was to contribute to the understanding of the 
mechanisms of action of VNS and to evaluate VNS therapy from a safety and 
effectiveness perspective. 
The specific aims were: 
§ To determine if a possible mechanism of action of VNS is the 
proliferation or increased survival of hippocampal progenitor 
cells. (Study I) 
 
§ To study the feasibility of a novel treatment for obesity in a rat 
model. (Study II) 
 
§ To describe the panorama of surgical and hardware 
complications to VNS implantation since its introduction in 
clinical trials at a single center. (Study III) 
 
§ To investigate the efficacy of VNS in combination with 
pharmacological therapy in a longitudinal study at a single 
center. (Study IV) 
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MATERIALS AND METHODS 
 
Methods when studying progenitor cell 
proliferation and survival in rat (study I) 
Animals 
The study was approved by the Gothenburg Regional Ethics Committee for 
Animal Experiments. 
All animals were male Sprague-Dawley rats weighing 200–300 g. Animals 
were kept and handled in accordance with the regulations of the Swedish 
Animal Welfare Agency. Animals were housed two per cage under standard 
conditions, including ad libitum access to food and water in a 12 h light/dark 
environment. All procedures were performed during the light period. In total, 
a number of 52 rats that were implanted with a VNS pulse generator. Six 
were excluded from the study because of adverse events, most commonly 
edema at the generator skin pocket. Approximately one-third of the rats 
developed a left sided postoperative ptosis, which persisted throughout the 
study period. 
Surgery 
All surgeries were performed under general anesthesia. To decrease 
postsurgical pain, the animals received subcutaneous buprenorphine 
preoperatively (0.03 mg/kg) and subcutaneous sterile saline (10 ml/kg) 
postoperatively. A ventral midline incision was made on the neck. The skin 
and muscles were retracted, and the left carotid artery and vagus nerve was 
identified. The left cervical vagus nerve was dissected from the carotid artery 
and the lead electrodes were wrapped around the nerve under microscopic 
control. The lead was then tunneled under the skin and the VNS therapy 
pulse generator NCP (Neuro Cybernetic Prosthesis) Model 102 (Cyberonics, 
Inc.; Houston, Texas) was connected and implanted in a subcutaneous pocket 
on the back of the rats, after which the wounds were closed. 
Study protocol 
After VNS surgery, rats were randomly assigned to either VNS, with output 
currents of 0.25 mA, 0.75 mA, 1.5 mA, or sham stimulation. All output 
currents were delivered at 20 Hz, 250 µsec pulse width, and duty cycle 30 s 
on and 5 min off. Twenty-four hours after surgery, the impedance of the 
stimulating electrodes was tested, and VNS was initiated for the rats assigned 
to the stimulation group. In the progenitor proliferation experiment, VNS 
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was delivered for 48 h after which the rats were sacrificed, and in the 
progenitor survival experiment, VNS was delivered for 2 weeks. Stimulator 
parameters were set according to an earlier study investigating VNS in rat 
and hippocampal NA increase105.  
Bromodeoxyuridine (BrdU) labeling was used to detect proliferating cells. 
BrdU is a thymidine analogue that is being incorporated into new DNA, 
which is formed during the cell division process. To detect the proliferation 
of progenitor cells, the rats received intraperitoneal injections of BrdU (200 
mg/kg) at 7:00 a.m. and 7:00 p.m. on day 2, and at 7:00 a.m. at day 3 of the 
experiment. The last injection was given 7 h before sacrifice. In this manner 
BrdU-incorporation into dividing cells occurred during several time points of 
the VNS treatment, enabling the evaluation of possible changes in 
proliferation rate in VNS-treated rats as compared to sham-operated animals. 
To analyze the effect of VNS on progenitor survival, BrdU was administered 
before the VNS stimulation was started149,238. BrdU (75 mg/kg) was 
administered 4 times with 2 hours in between to VNS implanted rats with 
devices turned off. VNS was then started 24 h after the last BrdU-injection. 
After two weeks of stimulation the VNS device was turned off, and the 
animals were left without stimulation for 2 weeks before sacrifice. 
Experimental paradigms are presented in Figure 4. 
 
Figure 4. Experimental paradigms. (A) Proliferation paradigm. VNS electrodes 
and stimulators were implanted and activated at day 1 in half of the rats, whereas 
the other half were sham treated rats identically handled but with no activation 
of the implanted VNS devices. On day 2 and day 3 BrdU-injections were given 
every 12th hour (3 injections in total) and the animals were sacrificed 7 h after 
the last BrdU-injection. (B) Survival paradigm. To examine the influence of VNS 
treatment on the survival of BrdU-labeled cells, BrdU was given to the animals 
before initiating VNS treatment. Rats were then sacrificed 28 days after BrdU-
injection (14 days after the last VNS treatment). The longer treatment time was 
used to ensure that even a small effect on survival would be detected.  
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Tissue preparation 
Rats were anesthetized and decapitated. The brains were removed and fixed 
in 5 % buffered formaldehyde for 24 h and thereafter kept in 30 % sucrose 
solution at 4 °C. Sectioning was performed on a freeze microtome. The 
immunohistochemistry experiments were performed on free-floating 
sections. In brief, the sections were denatured, endogenous peroxidase 
activity was removed, and sections were incubated with a monoclonal mouse 
anti-BrdU IgG antiserum. Sections were washed, incubated with biotinylated 
secondary horse anti-mouse IgG antiserum and allowed to react with avidin-
peroxidase. Finally, cells incorporated with BrdU were visualized with a 
detection solution. 
Data collection 
In each rat, the number of BrdU-positive cells in the granule cell layer (GCL) 
(including the subgranular layer) was determined in 12 immunoperoxidase-
stained, 40-μm-thick coronal sections per DG taken 240 μm apart. The 
number of BrdU-positive cells was counted within the GCL and two cell 
diameters below the GCL, ignoring the cells in the uppermost focal plane and 
focusing through the thickness of the section to avoid errors caused by 
oversampling239. Microscopy images were obtained with a Nikon Diaphot 
microscope equipped with a CCD camera. The results are expressed as mean 
BrdU-positive cells per section.  
 
All samples were assigned a code that obscured the identity of samples for the 
examiner. A limited number of VNS devices were available for the 
experiments, and this forced the extensive dose-response experiments to be 
performed at two separate time points.  
Figure 5. BrdU-positive 
cells in the hippocampus 
identified as black dots 
representing single cells or 
clusters of 3–10 cells 
(arrows). Most of the 
BrdU-positive cells 
showed irregularly shaped 
nuclei and coarse patterns 
of BrdU-staining, which 
are features of immature 
and dividing cells. 
(Courtesy of Journal of 
experimental neurology) 
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Methods when analyzing VBLOC in rat and 
its possible mechanism of action (study II) 
Animals  
The study was approved by the Norwegian National Animal Research 
Authority (Forsøksdyrutvalget, FDU).  
Animals were either male Sprague-Dawley rats (pilot experiment) or female 
Long Evan rats (second experiment). All applicable institutional and national 
guidelines for the care and use of animals were followed. All animals were 
housed three to four together under standard conditions with free access to 
tap water and standard rat pellet with a 12 h light/dark cycle. In total a 
number of 25 rats were implanted with a VNS pulse generator.  
Surgery 
All surgeries were performed under general anesthesia. Atropine was given at 
a dose of 0.04 mg/kg subcutaneously 20 min before anesthesia. All animals 
were injected with buprenorphine subcutaneously (0.05 mg/kg) 
postoperatively and one day after surgery when needed. Sterile saline (10 ml) 
was administered subcutaneously after surgery to keep the animals hydrated. 
VBLOC implantation was performed through a midline abdominal incision. 
The subdiaphragmatic vagus nerve was dissected from the esophagus and 
two electrodes (Lead Model 302, Cyberonics, Houston, TX) were wrapped 
around both the anterior and posterior nerve. The lead was then tunneled 
under the skin and connected to the VNS therapy pulse generator NCP 
(Neuro Cybernetic Prosthesis) Model 102 (Cyberonics, Inc.; Houston, Texas), 
which was implanted in a subcutaneous pocket on the back of the rats, and 
the wounds were closed. The sham and VBLOC rats underwent the same 
surgical procedure. Implantation of the µVBLOC device followed the same 
method. In the gastric acid secretion experiment, a gastric fistula was 
implanted in the stomach. Before this procedure the animals were fasted 
overnight, and after surgery they were given water immediately and food the 
same evening.  
Study protocol 
The paradigm of VBLOC between 0.5 and 2.0 mA with 30 Hz, 500 µsec pulse 
width, 30 s on, and 5 min off was chosen according to the safety, tolerance, 
and possible efficacy assessments in response to the long-term VBLOC. 
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Short-term VBLOC 
In the first experiment, rats (Sprague-Dawley) received VBLOC (2 mA, 30 
Hz, 500 µsec pulse width, 30 s on, and 5 min off) while they were subjected to 
electrophysiological recordings in the hippocampus. In the second 
experiment, rats (Sprague-Dawley) that had implanted gastric fistulae were 
acclimatized to Bollman cages for 3 h at three separate occasions before and 
after VBLOC and gastric fistula implantation, and then subjected to gastric 
acid secretion measurement (at baseline and after pentagastrin stimulation). 
After gastric acid output measurement, VBLOC was turned off. Three days 
after, rats received VBLOC (2 mA, 30 Hz, 500 µsec pulse width, 30 s on, and 5 
min off) for 48 h while eating behavior and metabolic parameters were 
measured in the Comprehensive Laboratory Animal Monitoring System 
(CLAMS)240. 
 
Long-Term VBLOC 
In the first experiment (Sprague-Dawley rats), VBLOC was started 4 weeks 
after implantation. The device was then constantly on while the current was 
gradually increased during 6–8 weeks. Each rat was placed in CLAMS at four 
time-points for measurements of eating behavior and metabolic parameters 3 
weeks after VBLOC implantation (before stimulation baseline), at 0.5 mA, at 1 
mA, and at 2 mA stimulation. The settings were 30 Hz, pulse width 500 µsec, 
and the on and off time were 30 s and 5 min. The VBLOC and sham groups 
consisted of nine and four rats per group.  
In the second experiment (Long Evan rats), we developed smaller VBLOC 
devices (µVBLOC) due to device-size-related irritation. The µVBLOC and 
sham groups consisted of four rats per group, and µVBLOC was continuously 
on at 2 mA, 30 Hz, 500 µsec, 30 s on, and 5 min off for 2 weeks. The sham 
group was implanted with the stimulators only, and no electrodes were used.  
Tissue preparation 
In the short-term experiment, rats were euthanized immediately after 48 h of 
VBLOC and brain samples were collected for in situ hybridization. Plasma 
was collected for radioimmunoassay. After euthanization in the first long-
term experiment, brain samples were taken for Taqman array analysis and 
RNA sequencing. Plasma was collected for radioimmunoassay as well in the 
second long-term experiment.  
Data collection 
Rats were placed in the CLAMS, with free access to standard rat powder food 
and tap water. This system is composed of a four-chamber open circuit 
indirect calorimeter designed for continuous monitoring of individual rats. 
Eating behavior and metabolic parameters were recorded automatically. In 
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all studies performed, food intake was higher and satiety ratio lower during 
nighttime than daytime for all animals at every time-point. 
Methods when compiling data on VNS 
safety and long-term efficacy          
(Studies III and IV) 
The study was approved by the Gothenburg Regional Ethics Committee for 
Human Research. 
In study III data from 247 consecutive patients implanted with a VNS device 
(Cyberonics Inc. or BioControl Medical) between January 1990 and 
December 2014 were compiled from patient journals and analyzed 
retrospectively. Apart from primary implantation, all stimulator 
replacements due to battery depletion were analyzed to determine the overall 
occurrence of surgical and hardware complications.  In total 497 procedures 
were performed over the time period. 
In study IV data from 130 consecutive patients implanted with a VNS device 
between the years 2000 and 2013 were analyzed. Seizure frequency and AED 
treatments were recorded prior to VNS implantation as well as at 1, 2, and 5 
years after implantation. 
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Statistical analyses 
Study I  
All data are presented as means ± standard error of mean (SEM). Statistical 
analyses were performed by one-way analysis of variance (ANOVA) followed 
by Bonferroni post hoc test for group comparisons in experiments that 
included more than two groups. For experiments involving two groups, the 
unpaired two-sided Student's t-test was used. Statistical significance was set 
at p<0.05.  
Study II  
The results are expressed as mean ± SEM. Statistical comparisons were 
performed using independent t-test between the surgical groups. ANCOVA 
with Sidak test was performed for energy expenditure statistics, while 
ANOVA with Tukey’s test was performed to determine eating behavior and 
metabolic parameters. A p-value of <0.05 was considered statistically 
significant. The data analysis was performed in SPSS version 15.0 and 20.0 
(IBM Corp., Armonk, NY, USA). 
Study II I  
Continuous variables are presented both as a mean with standard deviation 
(SD) and as a median with first and third quartile (Q1, Q3). Chi-square test 
was used for the comparison of distributions within groups. A p-value below 
0.05 was considered to be statistically significant. All statistical calculations 
were performed with SPSS version 22 (IBM Corp., Armonk, NY, USA).  
Study IV 
None of the continuous parameters were normally distributed (tested with 
Kolmogorov-Smirnov test and plotted in a histogram as well as a Q-Q-plot); 
thereby, data is presented as median with first and third quartile (Q1, Q3). 
Non-parametric tests (Mann Whitney U test and the paired Wilcoxon signed 
rank test) were used. Categorical parameters are presented with absolute 
numbers and percentage. For group comparisons, Fischer´s Exact test was 
used. Paired tests were used to evaluate changes in seizure frequency and 
numbers of AEDs at the different follow-up times. All significance tests were 
two-sided and conducted at the 5 % significance level. IBM SPSS Statistics, 
version 23 (IBM Corp, Armonk, NY, USA) was used for statistical analysis. 
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RESULTS 
Study I 
In the progenitor proliferation study, a significantly greater number of BrdU-
positive cells were seen in the 0.75 mA group compared to the sham control 
group, with 22.6 ± 2.1 respectively 14.6 ± 2.0 BrdU-positive cells per 
hippocampus slice (p=0.04). Regarding the dose-response rate, 0.75 mA 
stimulation current presented a significant increase in BrdU-positive cells 
compared to sham (with a 54 % relative increase, p=0.004), which was not 
shown for 0.5 mA and 1.5 mA (23 %, p=0.34, and 19 %, p=0.36, respectively). 
The greatest effect on progenitor proliferation was at the 0.75 mA output 
current (ANOVA-Bonferroni correction; sham control n=15). 
 
 
 
  
Figure 6. The number of BrdU-positive cells in the adult rat hippocampus was 
increased after VNS treatment for 48 h with 0.75 mA output current (mean ± 
SEM number of BrdU-positive cells; No. VNS=8, No. Sham=7). VNS treatment for 
48 h also increased BrdU-positive cells in the adult hippocampus dose 
dependently. Output currents of 0.75 mA (No.=8), but not 0.5 mA (No.=7) or 1.5 
mA (No.=6), significantly increased the number of BrdU-positive cells. (Courtesy 
of Journal of experimental neurology) 
In the progenitor survival study, there was no significant difference in the 
number of BrdU-positive cells with 8.3 ± 1.3 and 6.7 ± 1.4 (± SEM) BrdU-
positive cells per hippocampus slice in sham and VNS-treated animals 
respectively (p=0.420, Student's t-test, n=5.5). No difference in weight gain 
was observed between the sham and VNS-treated animals. 
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Study II 
In the short-term VBLOC study (48 h at 2mA current), no changes in body 
weight, food intake, eating behavior, or metabolic parameters including 
energy expenditure were observed.  
 
In the long-term VBLOC, in which the current was gradually increased (from 
0.5 to 2 mA), the body weight and food intake were reduced as the current 
increased, reaching reductions of 10 % (p>0.05) and 30 %  (p<0.05), 
respectively. Energy expenditure (kcal/h/body weight) was reduced 
compared to baseline values. Satiety ratio, particularly during nighttime, was 
increased, but the number of meals (“hunger index”) was unchanged. When 
the current was started at 2 mA, a 10 % body weight reduction was achieved 
within 1 week (p<0.05). Additional parameters of eating behavior and 
metabolism were unchanged after long-term VBLOC.  
Study III 
In total there were 37 surgical complications and 16 hardware complications 
in 47 different patients. The median follow-up time was 11.8 years (Q1 6.9, Q3 
17.7), and the mean follow-up time was 12.0 years (SD 6.5). Fifty-five of the 
patients were children (age range 4–17). Table 3 shows a summary of the 497 
surgical procedures performed. All complications are summarized in Table 4. 
Complications related to surgery occurred in 8.6 % of all procedures 
performed and the hardware complications rate was 3.7 %. The most 
common surgical complications were infection (2.6 %), postoperative 
hematoma (1.9 %), and vocal cord paralysis (1.4 %), and the most common 
Figure 7. No significant 
effects were seen from VNS 
on survival of BrdU-positive 
cells in the dentate gyrus 
after a 4 week survival 
paradigm (mean ± SEM 
number of BrdU-positive 
cells; No. VNS=5, No. 
Sham=5). (Courtesy of 
Journal of experimental 
neurology) 
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hardware-related complication was lead fracture/malfunction (3.0 %). The 
infection rate was 4 times higher between 2000 and 2014 compared to 
between 1990 and 1999 (3.3 % vs. 0.8 %, p=0.057). The rate of lead breaks was 
decreased 3.2-fold (2.3 % vs. 7.3 %, p=0.049) during the same time periods.   
 
Table 3. All VNS related procedures performed between 1990 and 2014 
Summary of surgical procedures  All Children Adults  
1990-
1999 
2000-
2014 
VNS implantation 247 55 192 89 158 
Plain stimulator replacement in one session 161 29 132 29 132 
System replacement in one session  8 2 6 2 6 
Plain lead replacement in one session 9 1 8 4 5 
Reimplantation of stimulator 4 1 3 0 4 
Explantation of stimulator 45 9 36 14 31 
Lead exploration 5 0 5 4 1 
Wound revision 5 0 5 1 4 
Explantation of lead 4 1 3 0 4 
Intentional stimulator replacement discont. 1 0 1 0 1 
Intentional lead replacement discontinued 1 0 1 1 0 
Reconnection of lead to stimulator 2 0 2 0 2 
Repositioning of lead 1 0 1 1 0 
Reposition of stimulator 2 0 2 1 1 
Removal of postoperative hematoma 2 0 2 0 2 
Total surgical procedures 49
7 
98 399 146 351 
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Table 4. All VNS surgery related complications between 1990 and 2014 
Complications All Children Adults  1990-1999 2000-2014 
          
Surgical complications (total) 37 (8.6 %) 6 (6.8 %) 31 (9.1 %) 11 (8.9 %) 28 (9.2 %) 
 
         Hematoma 8 (1.9 %) 1 (1.1 %) 7 (2.1 %) 2 (1.6 %) 6 (2.0 %) 
 
         Post primary implantation 7 (2.8 %*) 1 (1.8 %*) 6 (3.1 %*) 2 (2.2 %*) 5 (3.2 %*) 
 
         Post stimulator replacement 1 (0.6 %^) 0 (0 %^) 1 (0.7 %^) 0 (0 %^) 1 (0.7 %^) 
 
         Infections (all) 11 (2.6 %) 4 (4.5 %) 7 (2.1 %) 1 (0.8 %) 10 (3.3 %) 
 
         Post primary implantation 8 (3.2 %*) 4 (7.3 %*) 4 (2.1 %*) 0 (0 %*) 8 (5.1 %*) 
 
         Post stimulator replacement 2 (1.1 %^) 0 (0 %^) 2 (1.4 %^) 1 (2.9 %^) 1 (0.7 %^) 
 
         Post stimulator reimplantation 1 (% n. a.) 0 (% n. a.) 1 (% n. a.) 0 (0 %) 1 (0.3 %) 
 
         Vocal cord palsy (all) 6 (1.4 %) 0 (0 %) 6 (1.8 %) 3 (2.4 %) 3 (1.0 %) 
 
         Post primary implantation 5 (2.0 %*) 0 (0 %*) 5 (2.6 %*) 2 (2.2 %*) 3 (1.9 %*) 
 
         Post lead explant./replacement 1 (% n. a.) 0 (% n. a.) 1 (% n. a.) 1 (% n. a.) 0 (% n. a.) 
 
         Pain and sensory related  6 (1.4 %) 1 (1.1 %) 5 (1.5 %) 2 (1.6 %) 4 (1.3 %) 
 
         Technical complications (total) 16 (3.7 %) 0 (0 %) 16 (4.7 %) 9 (7.3 %) 7 (2.3 %) 
 
         Lead fracture/malfunction 13 (3.0 %) 0 (0 %) 13 (3.8 %) 8 (6.5 %) 5 (1.6 %) 
 
         Spontaneous VNS turn on  1 (0.2 %) 0 (0 %) 1 (0.3 %) 0 (0 %) 1 (0.3 %) 
 
         Lead disconnection 2 (0.5 %) 0 (0 %) 2 (0.6 %) 1 (0.8 %) 1 (0.3 %)  
          *Percentage of all n=247 / children n=55 / adults n=192 / female n=125 / male n=122 / 1990-1999 n=89 / 
2000-2014 n=158 VNS primary implantations 
^Percentage of all plain stimulator replacement in one session, system replacement in one session (stimulator 
and lead), plain lead replacement in one session, or reimplantation of stimulator (all n=174 / children n=33 / 
adults n=141 / female n=73 / male n=101 / 1990-1999 n=35 / 2000-2014 n=147) 
Study IV 
There was a significant seizure reduction overall (all p<0.001), and VNS 
efficacy increased with time. The responder (≥50 % seizure frequency 
reduction) rate increased from 22.1 % to 43.8 % between the first and fifth 
year, with the largest increase between the first and second year (22.1 % – 38.1 
%), for the cohort as a whole and regardless of AED changes. Out of 76 
patients with no seizure frequency reduction after 1 year, 12 patients (15.8 %) 
had a ≥50 % seizure frequency reduction and 2 patients (2.6 %) had a 1–49 % 
seizure frequency reduction at 2 years. Furthermore, out of 55 patients with 
no seizure frequency reduction after 2 years, 5 patients (9.1 %) had a ≥50 % 
seizure frequency reduction and 2 patients (3.6 %) had a 1–49 % seizure 
frequency reduction at 5 years. One out of 27 patients (3.7 %) who reported a 
≥50 % seizure reduction after 1 year returned to baseline seizure frequency 
after 2 years, and 4 out of 43 patients (9.3 %) who reported a ≥50 % seizure 
reduction after 2 years returned to baseline seizure frequency after 5 years. 
Only 2 patients became seizure free. 
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VNS efficacy did not differ between patients who altered or remained on the 
same AEDs. Patients were treated with a median of 3 AEDs throughout the 
study but the number of AEDs significantly increased after 2 (p=0.007) and 5 
(p=0.001) years. Table 6 shows the use and variation in AEDs during the 
study period. 
 
 
 
Figure 8. Seizure control outcomes at 1, 2, and 5 year follow-up with McHugh 
Outcome Classification. Arrows indicating changes in VNS efficacy between 
follow-ups. (*Patients lost to follow-up) 
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Table 5. Seizure frequency at follow-up 
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Table 6. Proportion of patients with specified number of AEDs before and after 
follow-ups 
No. of 
AEDs 
Before VNS 
(n=130)  
After 1 year  
(n=123) 
After 2 years 
(n=109) 
After 5 years 
(n=79) 
0 1 (0.8 %) 3 (2.4 %) 2 (1.8 %) 2 (2.5 %) 
1 13 (10.0 %) 13 (10.6 %) 6 (5.5 %) 2 (2.5 %) 
2 43 (33.1 %) 36 (29.3 %) 32 (29.4 %) 21 (26.6 %) 
3 48 (36.9 %) 40 (32.5 %) 38 (34.9 %) 25 (31.6 %) 
4 19 (14.6 %) 22 (17.9 %) 22 (20.2 %) 22 (27.9 %) 
5 6 (4.6 %) 8 (6.5 %) 7 (6.4 %) 4 (5.1 %) 
6 0 1 (0.8 %) 2 (1.8 %) 3 (3.8 %) 
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DISCUSSION 
Neurogenesis (study I) 
The positive effects on depression noticed in patients treated with VNS could 
be explained by an increased neurogenesis in the hippocampus. The results 
in Study I suggest that short-term VNS increases stem cell proliferation in 
the rat hippocampus. This supports the idea that hippocampal plasticity is 
involved in the treatment of depression and could be one of the mechanisms 
of action behind VNS. However, increased hippocampal neurogenesis can 
result from either increased progenitor cell proliferation, from enhanced 
progenitor survival with a decrease in the number of cells that normally 
succumb sometime after the cell division, or from a combination of both 
mechanisms241. Our results support the idea that progenitor cell proliferation 
and survival are regulated by different mechanisms, and that VNS can 
stimulate rapid cell proliferation in the hippocampus. This is believed to be 
facilitated through an increased noradrenergic release from the LC99,105. 
There is also evidence that the LC is involved in an increased indirect release 
of 5-HT in the hippocampus, since the LC has an excitatory influence on the 
serotoninergic dorsal raphe nucleus99,100. The increased 5-HT is, however, 
not as immediate as the NA release and could explain why antidepressant 
drugs induce progenitor cell proliferation in the hippocampus at a much 
slower pace, taking at least 2 weeks to induce cell proliferation120,149,158. The 
time delay in efficacy of antidepressants (in both humans and animal models) 
could also mirror the time required for newly proliferated neurons to become 
functional and hyperplastic242. Antidepressant drugs usually require 3–4 
weeks before any sign of improvement in humans243. In clinical depression 
studies, VNS seems to induce improvement after 3 month but this 
improvement increases with time up to 2 years134,244. This is most likely a 
result of a long-term neuromodulatory effect. The role of VNS in the 
treatment of depression is, and will probably remain, as an adjunctive 
therapy for severe chronic cases, which may have necessitated repeated 
electroconvulsive therapies with short remission periods.  
The up-regulation of progenitor cell proliferation appears to be dose 
dependent. The maximum effect was at an output current of 0.75 mA in 
Study I. This type of dose dependency has been reported in earlier 
experiments with long-term potentiation in the DG of the rat 
hippocampus245. The current 0.75 mA might be an optimal stimulation 
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parameter for progenitor cell proliferation in rats considering that there was 
a non-significant increase at 0.5 mA and 1.5 mA. On the other hand, the rat 
vagus nerve is approximately 25 times thinner than the human vagus nerve, 
and stimulation between 0.5 and 1.5 mA possibly actives the C-fibers as well. 
If extrapolating from animal data, stimulation with 0.125 mA would be 
sufficient to recruit C-fibers in the rat246. Hypothetically the C-fibers could be 
involved in the increase of progenitor cell proliferation in the rat 
hippocampus. 
However, the question still remains if the progenitor cells mature into new 
neurons and integrate into existing hippocampal networks, in order to 
restore brain function in depressed patients. So far, VNS has been shown to 
be a potent stimulator of progenitor cell proliferation in experimental animal 
studies, but this have been difficult to correlate with behavioral 
improvements157. This suggests that there is probably more than just 
increased progenitor cell proliferation in the hippocampus needed to explain 
VNS induced efficacy in depression.  
In animal studies the commonly used AEDs, carbamazepine, valproate, and 
lamotrigine have been found to cause an increase in hippocampal 5-HT247-249. 
These drugs seem to have mood stabilizing properties and are also used to 
treat psychiatric disorders, mainly bipolar affective disorder250. The 
anticonvulsant effect of carbamazepine can be blocked with 5-HT-depleting 
drugs in rats genetically prone to have seizures251, suggesting that some 
antiepileptic drugs and antidepressants could have similar mechanisms of 
action. In experimental studies lamotrigine seems to increase the number of 
BrdU-positive cells in the rat hippocampus, whereas valproic acid does not252. 
Lamotrigine has been suggested as an augmented treatment in unipolar 
depression253. However, a recently published double-blinded placebo-
controlled trial could not confirm its additive antidepressant effect254. Other 
antiepileptic drugs seem to have a negative effect on hippocampal 
neurogenesis, especially in the developing brain255,256. We hypothesize that 
the antidepressant mechanism of VNS through increased progenitor cell 
proliferation in the hippocampus is independent from its antiepileptic 
effects. However, further studies are needed to confirm this hypothesis. 
In addition, there is a bidirectional relationship between epilepsy and 
depression. Patients with DRE have an increased risk of developing MDD, 
and patients with primary psychiatric disorders pose an increased risk of 
developing epilepsy. This comorbidity suggests that there could be shared 
underlying pathologies.257 Since VNS has an impact on both epilepsy and 
depression it might be an optimal treatment in patients with DRE suffering 
from MDD. 
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Complications when implanting VNS in rat 
(Studies I and II) 
In Study I approximately one third of the rats suffered from a left sided 
ptosis postoperatively. This was believed to be Horner’s syndrome or 
oculosympathetic palsy. The phenomenon has been described as a 
complication of VNS implantation in rats258. In humans, one case of Horner’s 
syndrome have been reported after VNS implantation259. In Studies I and II 
some of the rats developed an aseptic fluid collection around the stimulator 
after a few days to weeks. This was believed to occur because of device size-
related irritation. In some cases the fluid was evacuated. Although these 
complications probably did not affect the results of Studies I and II, it is 
important to recognize that VNS implantation in rats can cause discomfort to 
the animals. This may be an ethical consideration in future studies. 
VBLOC (Study II) 
In order to accurately determine food intake, eating behavior, and metabolic 
parameters the state-of-the art CLAMS was used. CLAMS is particularly 
important when trying to analyze food consumption and weight reduction as 
accurately as possible in small rodents. Earlier experimental animal studies 
have reported a reduced body weight in response to VNS. However, these 
studies were mainly performed on the cervical vagus nerve260,261. In Study II, 
short-term (48 h) subdiaphragmatic blockage of the efferent vagus nerve did 
not alter eating behavior. Conversely, the long-term (6–8 weeks) VBLOC 
reduced food intake and body weight, particularly when being started with a 
high current. This is in line with a report that subdiaphragmatic VNS 
attenuated weight gain in obese minipigs during 14 weeks262. Data suggest 
that it is beneficial to start stimulation at a high current, rather than 
increasing it gradually, in order to achieve the body weight loss. On the other 
hand, one could speculate that starting with an initially high current without 
titration could cause aversive pain and thereby reduce food intake.  
Theoretically VBLOC could activate the vagal signaling to the brainstem and 
hypothalamus and inhibit the signaling to the gut, leading to increased 
satiety, reduced food intake, and ultimately loss of body weight. Considering 
the newly approved VBLOC treatment for obesity, more studies are needed 
to further investigate the mechanism of action, safety, and long-term data. 
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Complications of VNS implantation   
(Study III) 
Safety concerns must be seen in the long-term perspective since many 
patients receive their VNS at a young age with the expectancy to use it for 
many years. This includes a possible number of pulse generator replacement 
surgeries. To our knowledge Study III is the longest ever (up to 25 years, 
median 12 years) follow-up on surgical complications after VNS. With its 
longevity it covers not only immediate complications such as postoperative 
hematomas, wound infections, and vocal cord paralysis, but also more long-
term complications such as lead malfunction and lead breaks which are 
probably more prone to occur over time. It is reasonable to believe that the 
complication frequency increases with a longer follow-up time considering 
the repeated surgeries needed due to depleted stimulators and hardware 
being worn out. The overall complication rate in Study III was 12.4 %, 
including both surgical and hardware complications. Most previous studies 
present frequencies ranging from 2.5 % to 12.5 %24,38-42,218,263. However, they 
rarely account for overall complication rates and seldom separate surgical 
and hardware complications. There are also different opinions about what is 
considered a complication, i.e. should a technical complication be considered 
as a complication to surgery or not? In the National Swedish Epilepsy 
Surgery Register (NSESR), compiling data from all Swedish epilepsy 
surgeries, complication is defined as “an unwanted, unexpected, and 
uncommon event after a diagnostic or therapeutic procedure”264. A great 
strength at our center is that the majority of patients are followed-up by the 
same physicians, and all primary implantations and stimulator replacements 
are performed at the same clinic by a limited number of experienced 
surgeons. If a suspected complication occurs, the implanting surgeon is 
immediately consulted. In Study III the most common complication was 
infection (2.6 %), and this is in the lower range compared to most previous 
complication studies (2–12.5 %)24,25,32,34-42,265. In the pediatric population the 
infection rate was almost twice as high (4.5 %) as in the adult. This could be a 
result of excessive wound manipulation, especially in children with 
intellectual disabilities. Extra postoperative vigilance could perhaps resolve 
this problem. The infection almost exclusively occurs at the stimulator 
implantation site below the collarbone and rarely at the neck. All but two 
patients with infection had to have their stimulator removed for successful 
treatment with antibiotics, and in all but two of these cases the electrode was 
simply cut at the stimulator and left in place. This indicates that it is most 
often safe to leave the leads in place. The number of extracted VNS devices 
due to infection varies in the literature (50–100 %)34,41,43,266. This is probably 
because there are both superficial and deep infections involved, and the 
superficial infections are easier to treat with antibiotics than the deep 
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infections. However, some centers advocate complete removal of both 
stimulator and lead if an infection occurs266. Infection rates after stimulator 
replacement in our study was only 1.1 % suggesting that this is a fairly low risk 
procedure compared to primary implantation. Lead malfunction and lead 
fractures have decreased significantly over the last 15 years of implantation at 
our center (2000–2014). This is probably a result of the development of 
better and more durable hardware. Lead fractures are not always visible on 
radiography. Increased impedance in combination with worsened seizure 
control can indicate a damaged lead leading to surgical revision or 
replacement of the lead. Lead failure in the absence of visible lead fractures 
have sometimes been described as “microlesions” in the cable267. Cardiac 
complications are rare and seem to occur mainly in the operating theatre 
when the leads are tested26,30,39, resulting in bradycardia or short asystole. 
None of our patients have suffered from asystole during or after 
implantation, but atropine is always at hand during lead testing in the event 
of such an occurrence.  
Complications should possibly be graded in different categories depending on 
time of occurrence and outcome. Kahlow et al suggests a grading into minor 
and major complication, where minor complications resolves within 3 
months and a major complication is an event that hinders activity of daily 
living and lasts for more than 3 months, or any significant neurological 
deficit24. Perhaps an international registry database is the best solution for a 
more standardized and consistent follow-up regarding both complications 
and effectiveness.  
In conclusion, in order to minimize surgical complications VNS 
implantations should be restricted to experienced surgeons with detailed 
familiarity with the procedure at hand and attention to detail. 
VNS in drug refractory epilepsy      
(Studies III and IV) 
In western Sweden VNS is offered exclusively to patients who have failed a 
multidisciplinary epilepsy surgery evaluation or when epilepsy surgery itself 
has been unsuccessful. Even though pre-surgical evaluation has become 
more and more developed in recent years, with new seizure monitoring 
techniques and better imaging modalities, many patients are poor surgical 
candidates because of multifocal seizure origins or involvement of eloquent 
areas268. VNS can be offered to these patients as an adjunctive palliative 
neuromodulatory treatment. Considering the fairly low surgical risks 
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involved, VNS has several advantages compared to pharmacological 
treatments. Contrary to drugs, compliance is not an issue, as VNS is 
continuous. Cognitive side effects and somnolence that is often seen with 
AED use have not been reported in VNS therapy45. In contrast, it is reported 
that many patients treated with VNS for epilepsy and depression can improve 
in cognition and alertness226,269. Furthermore, if stimulation related side 
effects occur, the parameters can be altered in order to alleviate them. Other 
important benefits that have been reported are decreased seizure severity 
and shortened duration of ictal and postictal events270,271. VNS does not 
interact with pharmacological treatments, and whereas the effect of AEDs 
seems to decrease over time due to tolerance65, VNS tends to improve 
efficacy over time56,223,272. This improvement is reported in Study IV and was 
seen for up to 5 years post implantation. The largest increase was seen at 2 
years. The magnet provides additional safety and control for the patient and 
caregiver273. In addition, VNS is reversible and can be turned off and 
removed if necessary. In Study III the most common cause for removal of 
the VNS was lack of efficacy in combination with discomfort from the 
stimulator.  
Considering the fact that almost all patients implanted with VNS are treated 
with multiple AEDs, the question arises as to whether the reduction in 
seizure frequency is a result of VNS itself, the combination of VNS and AEDs, 
or merely a result of AED changes during VNS. There have only been two 
studies conducted so far without AED changes during follow-up, and the 
results were similar to most other studies but the follow-up time was limited 
(12–18 months)182,214. In Study IV we tried to account for AED changes and 
correlate them to the individual patient or group, and investigate if the actual 
response to VNS differed between patients who were on unchanged 
medication throughout the observation period compared to the patients with 
changes in AEDs. There were, however, no major differences in VNS efficacy 
between patients with altered medication compared to patients who 
remained on the same or withdrew AEDs during the follow-up period. The 
responder rate increased from 22.1 % to 43.8 % between the first and fifth 
year, with the largest increase between the first and second year (22.1 % to 
38.1 %), in the whole cohort and regardless of AED changes. Conversely, 
there were also patients that initially were responders, with a seizure 
frequency reduction ≥50 %, who with time became non-responders. In our 
cohort the median number of AEDs were 3, but some of the patients had 5 or 
6 different AEDs concomitantly. Some patients had up to 8 different 
medications during the follow-up period. The question whether there could 
be a synergistic effect between VNS and certain AEDs still remains unclear.  
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Seizure freedom is a rare phenomenon in patients treated with VNS, and this 
reflects the common impression that, in DRE, even if given a new drug or 
VNS, seizure freedom is seldom achieved65. Nevertheless, seizure freedom is 
the single best predictor of quality of life in patients with epilepsy274,275. In a 
recent meta-analysis of VNS, 8.2 % of the patients became seizure free after 
24–48 months, and seizure freedom was predicted by age of epilepsy onset 
>12 years and predominantly generalized seizures276. Earlier reports have 
suggested seizure freedom in <5 %277.	In Study IV, 2 patients (1.5 %) became 
seizure free. This is not in line with the recent meta-analysis, but could 
reflect the fact that longer follow-up time is essential when determining 
seizure freedom and that relapses may occur after periods of remission.  
In another recent meta-analysis the greatest benefit from VNS was seen in 
patients with posttraumatic epilepsy and with tuberous sclerosis, but patients 
with generalized epilepsy and children also benefited significantly from 
VNS277. Others have suggested that predictors of VNS response are low 
seizure frequency, temporal discharge on EEG-video, and the presence of an 
MRI lesion213. Study IV showed no difference in seizure frequency reduction 
between focal epilepsy and generalized epilepsy syndromes. Regarding 
etiology, the groups were too small for any statistical analyses to be made. It 
should be noted that in a recent meta-analysis, the number of patients that 
did not benefit from VNS at all was approximately 25 %277. Study IV presents 
a corresponding number (with no seizure frequency reduction) of 42.5 % 
after 5 years. However, the cut off between groups of patients with no benefit 
and patients with 1–49 % (McHugh class III) or 0–49 % seizure frequency 
reduction (Engel class IV) may in some cases be rather arbitrary and difficult 
to determine.  
The recently published PuLSE (Open Prospective Randomized Long-term 
Effectiveness) trial assessed whether VNS as a treatment adjunct to best 
medical practice is superior to best medical practice alone, in improving 
health related quality of life in patients with pharmacoresistant focal seizures. 
The multicenter study demonstrated that adjunctive VNS therapy after 12-
month follow-up was associated with significantly greater improvement in 
health related quality of life over best medical practice alone278. However, 
because of recruitment issues, the study was terminated prematurely and the 
enrolled number of patients did not meet the planned sample size. Sixty out 
of a 122 randomized patients completed the 1-year follow-up. When 
evaluating VNS effectiveness it is important not only to determine seizure 
reduction, but also other factors such as quality of life, pharmacological side-
effects, adverse events, and seizure severity. By definition effectiveness is the 
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extent to which an intervention produces an outcome under ordinary day-to-
day circumstances279.  
Many patients have intractable DRE and try multiple AEDs before they 
receive VNS. This procedure of trying multiple AEDs can require years of up-
titrating and down-titrating different AEDs but to no avail. Since the efficacy 
of VNS is similar to adding a new AED, but possibly with fewer side effects, 
the question remains if VNS should be implanted at an earlier stage. In 
theory one can reason that this is a fair suggestion. Patients with DRE may 
respond to pharmacological therapies for shorter or longer periods but later 
relapse280. Seizure aggravation is also an important limitation of current 
AEDs65. Evaluation of the efficacy of adding just one new AED can, therefore, 
take over a year to complete. Patients with successful epilepsy surgery can 
also relapse after initial seizure freedom281. Among patients with DRE, 5 % 
per year enter seizure remission, but approximately 70 % of patients that 
experience a 12-month or greater seizure remission eventually relapse280. 
Thus, it is of great importance that all patients with DRE are referred to an 
epilepsy center for proper evaluation and follow-up.  
VNS has a role in the treatment of refractory epilepsy but the regime on how 
to combine with AEDs or other treatments should be well thought through 
and monitored. Based on the results of Study IV, we suggest that VNS should 
be continuously and carefully evaluated for at least 2 years after implantation 
before deciding if it is helpful or not. Furthermore, since there seems to be 
increasing efficacy with time, a restrictive approach to AED changes should 
be applied if possible.  
In summary, VNS is a well-tolerated, low risk procedure for the treatment of 
DRE and chronic depression. It has also been proposed for the treatment of 
several other diseases and was recently approved as a treatment for obesity. 
Over the past years multiple experimental studies have been conducted to 
better understand the mechanisms of action of VNS, and a number of clinical 
studies have also been performed in order to evaluate new possible treatment 
indications. Increasing evidence suggests that there are several pathways 
involved in the mechanism of action of VNS. As new research is published, 
further discoveries will hopefully unravel the full potential of VNS. 
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Strengths and weaknesses 
Studies I and II  
The main strengths of these studies are that the experiments were performed 
in a strictly methodological fashion and that the control animals were 
implanted with stimulators as well. In Study I the individuals performing the 
cell-counting procedures were blinded to whether the specimen was from a 
rat that had received VNS or not. Nevertheless, results from animal studies 
should always be interpreted with caution, especially if results are translated 
directly to humans. Although the laboratory environment is created not to 
stress the animals, the nature of the experiment itself could propose an 
increased level of stress. This could of course affect the results, especially 
since stress is a known inhibitor of hippocampal progenitor proliferation142. 
It cannot be excluded that some form of low-level stress was generated in the 
1.5 mA group, which could affect the progenitor proliferation rate negatively. 
There is also a learning curve when it comes to animal surgery, and the 
anatomical variations between animals can result in more or less challenging 
procedures. The fact that some animals developed a left sided ptosis and a 
fluid collection around the implanted stimulator could reflect on this matter. 
However, both sham and stimulated rats were operated at all stages of the 
surgical learning curve and thereby, the effect of surgical experience should 
be equally distributed between groups. In Studies I and II, stimulation 
parameters were set in accordance with earlier similar studies, but there is no 
way of knowing if these were the ideal parameters for our experiments.  
Studies II I  and IV 
The strengths of the Studies III and IV are that they are population based, 
long-term studies with one of the longest registry follow-up periods in the 
world. Not only are primary implantations included, but also repeated 
surgeries such as battery and lead replacements. All surgeries were 
performed by a small number of surgeons, and between 1990 and 1999 one 
surgeon made all VNS implantations. On the other hand, analyzing registry 
data over a long time period can be difficult, especially since surgeries 
performed before 1997 were not registered automatically in the electronic 
charts at our hospital. Furthermore, different and rather small group sizes 
may have had an impact on the statistical analyses. Retrospective long-term 
studies also propose a challenge because of patients lost to follow-up and 
differences in the interpretation of VNS efficacy. It is not possible to conduct 
double-blinded randomized long-term studies in this patient population 
extending up to 25 years for ethical reasons and that it is simply not feasible. 
However, a prospective randomized study would have lifted the results up to 
a higher level of evidence. Differences in the extent and manner of 
documentation between physicians can also be a limiting factor when 
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analyzing retrospective data. Drug responsiveness of a patient’s epilepsy 
should be regarded as a dynamic process rather than a fixed state. Instead of 
being constant, the course of epilepsy sometimes fluctuates282. Natural 
fluctuations in epilepsy can in part explain relapses in patients who otherwise 
are considered as responders. 
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CONCLUSIONS 
The main findings of this thesis were that: 
• VNS in the rat increases stem cell proliferation in the 
hippocampus, which supports the notion that hippocampal 
plasticity is involved in the antidepressant effect of VNS. 
(Study I) 
 
• VNS did not effect progenitor cell survival in the rat 
hippocampus. (Study I) 
 
• The mechanism of action of VBLOC as a treatment for 
obesity could be regulated by inducing satiety through vagal 
signaling, leading to reduced food intake and loss of body 
weight. The treatment was well tolerated in rats. (Study II) 
 
• The most common complications to VNS implantation, with 
an occurrence rate of about 2 %, were infection, 
postoperative hematoma, and vocal cord paralysis. (Study 
III) 
 
• Hardware quality has improved since the introduction of 
VNS, and significantly less lead associated complications 
occurred during 2000–2014 compared to 1990–1999. (Study 
III) 
 
• VNS efficacy did not differ between patients that had altered 
or remained on the same AEDs throughout the study period. 
(Study IV) 
 
• VNS efficacy increases with time with improvements seen 
up to 5 years after VNS implantation. (Study IV) 
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FUTURE PERSPECTIVES 
Recently two non-invasive devices for external VNS have been introduced on 
the European market. The NEMOS (Cerbomed, Erlangen, Germany) is an 
external device that provides transcutaneous VNS (tVNS) by using an intra 
auricular electrode, which stimulates the auricular branch of the vagus nerve. 
The device is approved for epilepsy. The gammaCore (electroCore LLC, 
Basking Ridge, NJ USA) is a handheld non-invasive VNS device (nVNS) that 
is held against the neck and provides a single 180-second burst of VNS. The 
nVNS is approved for the treatment of primary headache, 
bronchoconstriction, epilepsy, gastric motility disorders, anxiety, and 
depression. So far, only very small, mainly feasibility and proof-of-concept 
studies have been conducted on epilepsy for the NEMOS283, and none for the 
gammaCore284. More studies will hopefully cast a light on whether these 
treatments can become an alternative to invasive VNS. One can speculate 
that instead of implanting a VNS device immediately, a test trial with an 
external device could be performed to investigate if the patient is likely to be 
a responder to VNS. Hopefully this could reduce the number of implanted 
patients not responding to VNS. It could also give the patient a premonition 
of the stimulation related adverse events, such as voice alterations and 
hoarseness.  
In other neuromodulatory treatments such as spinal cord stimulation (SCS) 
and deep brain stimulation (DBS), there are several rechargeable alternatives 
on the market. With rechargeable VNS devices, repeated surgeries due to 
depleted batteries could be avoided and lower the complication risk. 
With Studies III and IV comprising the adverse events for up to 25 years and 
the efficacy for up to five years, as well as multiple other long-term studies, 
further retrospective cohort studies are no longer needed. There is today 
evidence for the effectiveness of VNS in epilepsy. Future studies could, 
however, be prospective randomized controlled trials focusing on VNS in 
combination with specific pharmacological treatments or on special patient 
groups who might benefit more than others from VNS therapy.  
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